In May 2024, the Eurasian Community for Access to Treatment (ECAT) held a meeting in Istanbul focused on expanding access to tuberculosis (TB) treatment. The event was organized by ITPC EECA in collaboration with the European Coalition Against TB. The meeting minutes are available in the attachments in English.
Emcure was founded in 1983 in India. In addition to ARVs, the company produces a wide range of other drug products. In addition to finished products, the company produces active pharmaceutical ingredients.
Emcure was founded in 1983 in India. In addition to ARVs, the company produces a wide range of other drug products. In addition to finished products, the company produces active pharmaceutical ingredients, which means that the company has a full production cycle.
One of the largest manufacturers of ARVs and API in the world.
Hetero is one of India’s leading generic pharmaceutical companies and the world’s largest producer of anti-retroviral drugs. Hetero’s business includes APIs, generics, biosimilars, custom pharmaceutical services, and branded generics.
TB-Alliance is a non-profit organization founded in 2000 to develop and market new, more effective drugs for the treatment of tuberculosis with a shorter treatment duration. It is a partnership that develops drugs located in New York and South Africa. TB-Alliance works in close partnership with pharmaceutical companies, research institutes and community around the world.
The meeting minutes with Gilead Sciences (including the meetings between EECA CAB and the company).
The meeting minutes with Janssen (including the meetings between EECA CAB and the company).
The meeting minutes with MSD (including the meetings between EECA CAB and the company).
The meeting minutes with ViiV Healthcare (including the meetings between EECA CAB and the company).
